Conversion of recent-onset Atrial Fibrillation by a single oral dose of Pilsicainide (Pilsicainide Suppression Trial on atrial fibrillation). The PSTAF Investigators

H Atarashi; H Inoue; K Hiejima; H Hayakawa

doi:10.1016/s0002-9149(96)00401-8

Conversion of recent-onset Atrial Fibrillation by a single oral dose of Pilsicainide (Pilsicainide Suppression Trial on atrial fibrillation). The PSTAF Investigators

Am J Cardiol. 1996 Sep 15;78(6):694-7. doi: 10.1016/s0002-9149(96)00401-8.

Authors

H Atarashi¹, H Inoue, K Hiejima, H Hayakawa

Affiliation

¹ First Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.

PMID: 8831412
DOI: 10.1016/s0002-9149(96)00401-8

Abstract

The efficacy and safety of a single oral dose of 150-mg pilsicainide, a new class Ic antiarrhythmic drug, in converting recent-onset atrial fibrillation to sinus rhythm were evaluated in 75 patients (51 men, 24 women; age 23 to 74 years). Conversion to sinus rhythm was achieved within 90 minutes in 45% of patients given pilsicainide and in 8.6% of those on placebo (p < 0.01), with no major adverse effects.

Publication types

Clinical Trial
Multicenter Study
Randomized Controlled Trial

MeSH terms

Administration, Oral
Adult
Aged
Anti-Arrhythmia Agents / administration & dosage*
Anti-Arrhythmia Agents / adverse effects
Atrial Fibrillation / drug therapy*
Atrial Fibrillation / etiology
Double-Blind Method
Female
Humans
Lidocaine / administration & dosage
Lidocaine / adverse effects
Lidocaine / analogs & derivatives*
Male
Middle Aged
Time Factors
Treatment Outcome

Substances

Anti-Arrhythmia Agents
Lidocaine
pilsicainide